Enveric Biosciences, Inc. — Income Charts
8 quarters of history · ending 2025-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+226.3% +$491
$274
Cost of Revenue
—
Gross Profit
—
R&D↓-49.9% -$400K
$402K
SG&A
—
D&A↓-52.4% -$44K
$40K
Operating Income↑+10.0% +$209K
$-2M
EBITDA↑+8.2% +$165K
$-2M
Interest Expense
—
Interest Income
—
Other Income/Expense↑+132.6% +$1K
$274
Pretax Income↑+10.1% +$210K
$-2M
Tax Provision↓-67.7% -$15K
$7K
Net Income↑+10.1% +$210K
$-2M
Gross Margin
—
Operating Margin↓-1643917.1pts
-683920.8%
Net Margin↓-1644204.2pts
-683820.8%
Effective Tax Rate
0.0%
Deferred Tax Assets
—
Deferred Tax Liabilities
—
NOL Carryforwards
$7M
ETR (Continuing Operations)↓-0.1pts
0.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.9pts
-2.1%
ETR Foreign Differential (pp)↑+5.1pts
2.1%
Operating Lease Cost
—
Revenue YoY Variation↑+336.0pts
226.3%
Income YoY Variation↓-29.5pts
10.0%
Revenue QoQ Variation↑+827.6pts
307.6%
Income QoQ Variation↑+35.4pts
25.6%